Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

Borst, Gerben R; Kumareswaran, Ramya; Yücel, Hatice; Telli, Seyda; Do, Trevor; McKee, Trevor; Zafarana, Gaetano; Jonkers, Jos; Verheij, Marcel; O'Connor, Mark J; Rottenberg, Sven; Bristow, Robert G (2017). Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. OncoTarget, 8(50), pp. 87638-87646. Impact Journals LLC 10.18632/oncotarget.20936

[img]
Preview
Text
20936-299517-4-PB.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (2MB) | Preview

Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer increasing the therapeutic ratio for olaparib may come from its ability to modify the tumour microenvironment by targeting homologous recombination-deficient, hypoxic tumour clonogens, and/or increasing tumour-associated vasodilation to improve oxygenation. Herein, we investigated the effect of prolonged neoadjuvant exposure to olaparib on the tumor microenvironment using a genetically-engineered mouse p53-/- syngeneic breast cancer model, which is proficient in homology-directed DNA repair. We observed increasedgrowth delay and decreasedclonogenic survival following pre-treatment with olaparib 50 mg/kg bid Olaparib for 7 days ending 48 hours prior to a radiation dose of 12Gy. This increasedradioresponse was associated with a decreased hypoxic fraction. This study suggests that the radiation response in patients can be improved with limited toxicity if olaparib is given in a purely neoadjuvant setting to modify the tumor microenviroment prior to the start of the radiotherapy treatment. Consequently a significant gain can be achieved in therapeutic window and clinical studies are needed to confirm this preclinical data.

Item Type:

Journal Article (Original Article)

Division/Institute:

05 Veterinary Medicine > Research Foci > Host-Pathogen Interaction
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP) > Institute of Animal Pathology
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP)

UniBE Contributor:

Rottenberg, Sven

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health
600 Technology > 630 Agriculture

ISSN:

1949-2553

Publisher:

Impact Journals LLC

Language:

English

Submitter:

Achim Braun Parham

Date Deposited:

08 May 2018 15:37

Last Modified:

08 May 2018 15:45

Publisher DOI:

10.18632/oncotarget.20936

PubMed ID:

29152107

Uncontrolled Keywords:

hypoxia neoadjuvant treatment olaparib radiotherapy targeted therapy

BORIS DOI:

10.7892/boris.112033

URI:

https://boris.unibe.ch/id/eprint/112033

Actions (login required)

Edit item Edit item
Provide Feedback